GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » Piotroski F-Score

Microbix Biosystems (TSX:MBX) Piotroski F-Score : 8 (As of Jun. 13, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Microbix Biosystems has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Microbix Biosystems's Piotroski F-Score or its related term are showing as below:

TSX:MBX' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of Microbix Biosystems was 9. The lowest was 1. And the median was 5.


Microbix Biosystems Piotroski F-Score Historical Data

The historical data trend for Microbix Biosystems's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems Piotroski F-Score Chart

Microbix Biosystems Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.00 7.00 6.00 1.00

Microbix Biosystems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 1.00 6.00 8.00

Competitive Comparison of Microbix Biosystems's Piotroski F-Score

For the Biotechnology subindustry, Microbix Biosystems's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -0.769 + 1.997 + 2.455 + 0.378 = C$4.06 Mil.
Cash Flow from Operations was 2.131 + -1.456 + 1.339 + 0.839 = C$2.85 Mil.
Revenue was 5.53 + 4.264 + 8.408 + 5.633 = C$23.84 Mil.
Gross Profit was 2.343 + 1.425 + 6.222 + 2.971 = C$12.96 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(33.194 + 34.295 + 35.653 + 36.707 + 37.922) / 5 = C$35.5542 Mil.
Total Assets at the begining of this year (Mar23) was C$33.19 Mil.
Long-Term Debt & Capital Lease Obligation was C$6.45 Mil.
Total Current Assets was C$24.68 Mil.
Total Current Liabilities was C$3.72 Mil.
Net Income was 0.639 + -0.464 + -1.299 + 0.032 = C$-1.09 Mil.

Revenue was 5.011 + 4.329 + 2.502 + 4.218 = C$16.06 Mil.
Gross Profit was 2.766 + 2.021 + 1.186 + 2.527 = C$8.50 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(32.947 + 33.296 + 33.145 + 32.694 + 33.194) / 5 = C$33.0552 Mil.
Total Assets at the begining of last year (Mar22) was C$32.95 Mil.
Long-Term Debt & Capital Lease Obligation was C$6.28 Mil.
Total Current Assets was C$22.31 Mil.
Total Current Liabilities was C$3.55 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Microbix Biosystems's current Net Income (TTM) was 4.06. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Microbix Biosystems's current Cash Flow from Operations (TTM) was 2.85. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=4.061/33.194
=0.12234139

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-1.092/32.947
=-0.03314414

Microbix Biosystems's return on assets of this year was 0.12234139. Microbix Biosystems's return on assets of last year was -0.03314414. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Microbix Biosystems's current Net Income (TTM) was 4.06. Microbix Biosystems's current Cash Flow from Operations (TTM) was 2.85. ==> 2.85 <= 4.06 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=6.447/35.5542
=0.18132879

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=6.28/33.0552
=0.18998524

Microbix Biosystems's gearing of this year was 0.18132879. Microbix Biosystems's gearing of last year was 0.18998524. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=24.683/3.719
=6.63699919

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=22.309/3.549
=6.28599606

Microbix Biosystems's current ratio of this year was 6.63699919. Microbix Biosystems's current ratio of last year was 6.28599606. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Microbix Biosystems's number of shares in issue this year was 139.117. Microbix Biosystems's number of shares in issue last year was 146.623. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=12.961/23.835
=0.54378016

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=8.5/16.06
=0.52926526

Microbix Biosystems's gross margin of this year was 0.54378016. Microbix Biosystems's gross margin of last year was 0.52926526. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=23.835/33.194
=0.71805146

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=16.06/32.947
=0.48744954

Microbix Biosystems's asset turnover of this year was 0.71805146. Microbix Biosystems's asset turnover of last year was 0.48744954. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Microbix Biosystems has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Microbix Biosystems  (TSX:MBX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Microbix Biosystems Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems (TSX:MBX) Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Executives
James Stuart Currie Senior Officer

Microbix Biosystems (TSX:MBX) Headlines

No Headlines